secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034708
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma appoints co-founder Matthew D'Onofrio as CEO, succeeding Dave Gonyer effective March 31, 2024
--------------------------------------------------------------------------------

- Dave A. Gonyer resigns as CEO and Board member effective March 31, 2024 for personal reasons; no disagreement with Company.
- Matthew J. D'Onofrio appointed CEO and Board member effective March 31, 2024.
- D'Onofrio is co-founder, previously President, COO, Secretary and Treasurer since February 2023.
- No family relationships or material interests in transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/0000950170-24-034708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/evok-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer